Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

UDG Healthcare — Update 21 July 2016

UDG Healthcare — Update 21 July 2016

UDG Healthcare

Written by

Andrey Litvin

Energy and Resources Analyst

UDG Healthcare

Updating estimates on H116, FX moves

Valuation update

Healthcare equipment & services

21 July 2016

Price

585.0p

Market cap

£1,441m

£/€1.20

Net debt (€m) at H116

246

Shares in issue

246.3m

Free float

100%

Code

UDG

Primary exchange

LSE

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

0.5

(1.7)

15.5

Rel (local)

(6.0)

(5.5)

17.2

52-week high/low

625.0p

460.3p

Business description

UDG Healthcare is a leading international provider of services to healthcare manufacturers and pharmacies. It employs 8,300 staff and is present in 22 countries. It operates across three divisions: Ashfield Commercial & Medical Services, Supply Chain Services and Sharp Packaging Services.

Next events

Capital markets day

27 September 2016

Preliminary FY16 results

24 November 2016

Analyst

Andrey Litvin

+44 (0)20 3077 5727

UDG Healthcare is a research client of Edison Investment Research Limited

We are updating our forecasts for UDG on the back of solid H116 results, the completion of the sale of the drug distribution business and recent pronounced currency moves. While providing a sufficient cash cushion in the current volatile market conditions, the divestment will allow increased flexibility for the company to deliver on its already successful track record of acquisitions. We raise our DCF valuation from £5.21 to £6.45/share.

Year
end

Revenue (€m)

EBITDA
(€m)

EPS*
(c)

DPS
(c)

P/E
(x)

Yield
(%)

09/14

764.2

97.7

23.2

10.1

30.3

1.4

09/15

919.3

126.1

27.4

11.0

25.6

1.6

09/16e

974.9

128.8

28.6

11.5

24.5

1.6

09/17e

1,020.2

134.6

31.1

12.5

22.6

1.8

Note: EPS for the period is normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments, and fully diluted

Solid H116 performance supported by currencies

UDG reported encouraging H116 results, with both Ashfield and Sharp Packaging divisions delivering solid underlying earnings growth supported by positive FX moves. Ashfield’s H116 revenue and operating profit were up 3% and 7%, leading to a 0.4pp margin expansion to 9.6%. While the division’s UK revenue slid 2% in local currency terms (assuming all in £), its operating margin improved to 12.5% (vs 11.4% in H115) against the backdrop of an 8% increase in underlying operating profit. By contrast, Ashfield’s North America revenue and operating profit fell 2% and 10% in dollar terms (although EBIT was up 15% when adjusted for the sale of Speaker Bureau in 2015). Most notably, Sharp’s US revenue grew 28% y-o-y (18% in dollar terms), while operating profit jumped 38% (27% in $) and margin reached 15.2% (vs 14.2% in H115). Sharp’s overall operating profit was up 25% y-o-y in constant currency terms, while the margin came in at 12.2%, up 1.6pp on H115.

Favourable US market conditions, adverse FX moves

UDG’s H116 results were to a large extent driven by Sharp’s US business, which continued to benefit from strong market demand and high utilisation rates. We expect this performance to be sustained in H216 and 2017 as an incremental 30% increase in US capacity comes on stream, allowing the company to capitalise on favourable market conditions. That said, the recent pronounced currency moves, with sterling weakening against the euro, will adversely affect results in H216, partly offsetting the US strength. On an underlying basis, though, we believe that UDG is well positioned to benefit from an increasing industry trend towards outsourcing.

Valuation: Upgrading on H116 results, lower WACC

We increase our DCF-derived valuation of UDG from £5.21/share to £6.45/share to reflect the H116 results, FX moves and lower WACC. Any extra value that might be generated from the capital reinvestment in line with the company’s acquisitive strategy would represent upside to our valuation. Thus, investing €500m at 11.0x EV/EBIT would move our valuation to £7.16/share. Overall, we believe that UDG’s stock continues to represent an attractive opportunity for investors looking to increase exposure to the sector while avoiding the inherent binary risk.

Updating earnings estimates and valuation

Solid H116 results, but H2 looks more challenging

UDG delivered an encouraging set of H116 results, with revenue and adjusted (for amortisation of acquired intangibles and transaction costs) operating profit rising 6% and 15% y-o-y to €472m and €48m respectively. On a constant currency basis, the company reported 2% and 9% increase in revenue and adjusted operating profit, respectively. The overall adjusted EBIT margin came in at 10.2% vs 9.4% in H115 and 10.7% in FY15. The results were driven by the strong performance of Sharp’s US business, which saw a 28% jump in revenue (up 18% in dollar terms) and a 38% increase in EBIT (up 27% in $), with margin expanding to 15.2% vs 14.2% in H115. Ashfield did not perform as strongly though, with positive currency moves offsetting a somewhat mixed underlying performance. The UK business has seen its revenue in local currency (assuming all in sterling) falling 2%, with EBIT rising 8%, resulting in a margin expansion to 12.5% vs 11.4% in H115. Ashfield’s US revenue slid by 2% and operating profit fell 10% compared to H115. However, adjusting for the disposal of Speaker Bureau in 2015, operating profit in the US grew by 15%.

We now forecast UDG to achieve 6.1% revenue growth in FY16 (€975m at £/€1.29 vs €1,016m before at £/€1.32). Apart from the revised exchange rates (in line with the prevailing forward curve), we are more cautious on the performance of the UK and European businesses following Brexit. That said, we understand that UDG’s UK business trades within the UK and the company expects it to remain resilient. We also highlight the increased (and growing) share of the US business, which allows for earnings diversification. However, a weaker sterling will have a negative impact on results in H216. At the same time, we expect Sharp’s strong performance in the US (10% of total revenue, 33% of EBIT in H116) to continue, compensating for the potential weakness elsewhere. With a 30% increase in production capacity following the completion of the new packaging facility in Pennsylvania and strong local demand, we expect Sharp’s US revenue to reach $257m in FY16, 17% y-o-y growth which, at a $40m full-year EBIT contribution, would imply a margin of 15.7%.

Overall, we forecast UDG’s FY16 adjusted operating profit to come in at €107m (from €102m), broadly in line with BBG consensus (EBIT of €102m, EBITDA of €128m). Despite lower revenue estimates, our updated earnings forecasts reflect improved profitability as we now model 36.0% gross margin vs 34.5% before. At the bottom line, we forecast UDG’s FY16 EPS for the period at 28.8c (adjusted for exceptional items), a 4.5% increase on FY15.

Exhibit 1: Summary of financial forecasts

€m

2015

H116

H216e

2016e

2017e

Supply Chain Services

99.9

48.8

50.0

98.8

101.3

Ashfield*

599.4

291.2

303.2

594.4

602.4

Sharp Packaging

244.1

132.4

149.4

281.8

316.5

Total revenue from continuing operations

919.3

472.4

502.5

974.9

1,020.2

COGS

581.7

303.8

320.1

623.9

652.9

Gross profit

337.6

168.6

182.3

351.0

367.3

SG&A

223.6

111.7

115.4

227.2

237.7

Admin

16.1

8.6

8.9

17.5

18.4

EBIT (adjusted for exceptional items)

98.5

48.4

58.4

106.8

111.6

EBIT

68.9

40.2

234.6

274.9

95.8

EBITDA (adjusted for exceptional items)

126.1

58.5

70.3

128.8

134.6

Profit before tax from cont. operations

55.8

33.1

231.1

264.2

99.8

Net profit from cont. operations, pre-exceptional items

54.2

25.2

37.4

62.6

76.8

EPS from cont. operations, pre-exceptional items (c)

22.2

10.3

15.2

25.4

31.2

Net profit for the period, pre-exceptional items

67.2

31.4

39.4

70.8

76.8

EPS for the period, pre-exceptional items (c)

27.5

12.7

16.0

28.8

31.2

Source: UDG, Edison Investment Research. Note: *Ashfield’s 2015 revenue includes discontinued MASTA. H116 average exchange rates £/€1.34, €/£1.10.

Exhibit 2: Revenue composition by region

Exhibit 3: Operating profit composition by region

Source: UDG, Edison Investment Research. Note: Assuming Aquilant’s revenue is 50% UK/50% EU.

Source: UDG, Edison Investment Research. Note: Assuming Aquilant’s EBIT is 50% UK/50% EU.

Exhibit 2: Revenue composition by region

Source: UDG, Edison Investment Research. Note: Assuming Aquilant’s revenue is 50% UK/50% EU.

Exhibit 3: Operating profit composition by region

Source: UDG, Edison Investment Research. Note: Assuming Aquilant’s EBIT is 50% UK/50% EU.

Valuation: Upgrading DCF on H116 results, FX, lower WACC

We increase our DCF-derived valuation of UDG from £5.21 to £6.45/share to reflect the recently released H116 results, FX moves and lower WACC (6.3% now vs 7.4% before). The latter has the most pronounced impact on the valuation, as we have reduced the risk-free rate from 0.70% to 0.25% against the backdrop of negative government bond yields and adjusted our beta estimate to 0.75 (vs 0.90) to bring it in line with Bloomberg (ytd adjusted beta estimate 0.72). We note that any extra value that might be generated from the reinvestment of available capital (FY16e cash of €443m, net cash of €146m) in line with the company’s acquisitive strategy (to this end, we note the recently announced purchase of Pegasus PR for an initial consideration of £10m) would represent upside to our valuation. On our estimates, investing some €500m at 11.0x EV/EBIT (the stock currently trades at an FY17e EV/EBIT (adjusted) of 11.4x and EV/EBITDA of 9.4x) would increase the valuation to £7.16/share. The company uses a prudent 15% ROCE target over three years when considering acquisitions. All in all, we believe that UDG’s shares continue to represent an attractive investment proposition for investors looking to increase their exposure to the sector while avoiding the inherent binary risk. In addition, we note a healthy dividend yield of 1.6% (FY16e) and would not rule out a one-off increase in dividends should the company decide to return capital to shareholders following the recent successful sale of the drug distribution business.

Exhibit 4: Base-case DCF calculation

€m

2016e

2017e

2018e

2019e

2020e

2021e

2022e

EBIT

106.8

111.6

115.6

120.0

123.2

126.3

129.5

Tax rate

23.0%

23.0%

23.0%

23.0%

23.0%

23.0%

23.0%

Tax

24.6

25.7

26.6

27.6

28.3

29.0

29.8

NOPAT

82.2

85.9

89.0

92.4

94.8

97.2

99.7

DD&A, impairments

37.0

38.8

40.2

41.8

42.9

44.0

48.7

Working capital

-1.8

-3.3

-2.7

-3.0

-2.1

-2.1

-2.2

Capex and acquisitions

301.9

-56.0

-52.6

-54.5

-55.8

-57.1

-58.5

Free cash flow

419.4

65.4

73.9

76.7

79.8

82.0

87.8

WACC, %

6.25

6.25

6.25

6.25

6.25

6.25

6.25

Present value of FCF

394.7

58.0

61.6

60.2

58.9

57.0

57.4

Total PV of FCF

748

 

 

 

 

 

 

Terminal value

2,107

 

 

 

 

 

 

Terminal growth rate

2.0%

 

 

 

 

 

 

PV of terminal value

1,378

 

 

 

 

 

 

Total enterprise value

2,126

 

 

 

 

 

 

Net debt/(cash) (2015)

223

 

 

 

 

 

 

Equity value

1,903

 

 

 

 

 

 

Total number of shares (m) (H116)

246

 

 

 

 

 

 

Value per share (£)

6.45

 

 

 

 

 

 

Source: Edison Investment Research

Exhibit 5: Financial summary

€m

2014

2015

2016e

2017e

2018e

Year end 30 September

IFRS

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

764

919

975

1,020

1,057

Cost of Sales

(497)

(582)

(624)

(653)

(677)

Gross Profit

267

338

351

367

381

EBITDA

 

98

126

129

135

139

Operating Profit (before GW and except)

 

75

99

107

112

116

Intangible Amortisation

(16)

(19)

(19)

(19)

(20)

Exceptionals

62

(15)

183

0

0

Operating Profit

124

69

275

96

99

Other

0

0

0

0

0

Net Interest

(16)

(13)

(11)

4

5

Profit Before Tax (norm)

 

46

70

81

100

104

Profit Before Tax (IFRS)

 

108

56

264

100

104

Tax (cont. operations)

(10)

(16)

(18)

(23)

(24)

Net profit from cont. operations after tax (norm)

36

54

63

77

80

Net profit from cont. operations after tax (IFRS)

98

42

246

77

80

Profit After Tax (discontinued operations)

13

13

9

0

0

Minority interest

0

0

0

0

0

Net profit for the period (norm)

56

67

71

77

80

Net profit for the period (IFRS)

110

55

255

77

80

Average Number of Shares Outstanding (m)

242

244

246

246

246

EPS from cont. operations - normalised fully diluted (c)

 

14.7

22.1

25.3

31.1

32.3

EPS for the period - normalised fully diluted (c)

 

23.2

27.4

28.6

31.1

32.3

Dividend per share (c)

10.1

11.0

11.5

12.5

13.0

Gross Margin (%)

35.0%

36.7%

36.0%

36.0%

36.0%

EBITDA Margin (%)

12.8%

13.7%

13.2%

13.2%

13.2%

Operating Margin (before GW and except.) (%)

9.9%

10.7%

11.0%

10.9%

10.9%

BALANCE SHEET

Fixed Assets

 

698

640

682

702

717

Intangible Assets

490

460

467

468

469

Tangible Assets

174

118

144

156

162

Other

34

62

70

78

86

Current Assets

 

738

955

726

761

802

Stocks

168

55

58

61

63

Debtors

407

205

218

228

236

Cash

160

214

443

466

496

Other (2015: Including assets held for sale)

3

480

6

6

6

Current Liabilities

 

(434)

(516)

(250)

(259)

(267)

Creditors

(422)

(192)

(206)

(215)

(223)

Other (2015: Including liabilities held for sale)

(12)

(324)

(44)

(44)

(44)

Long Term Liabilities

 

(468)

(470)

(331)

(331)

(331)

Long term borrowings

(391)

(416)

(277)

(277)

(277)

Other long term liabilities

(76)

(54)

(54)

(54)

(54)

Net Assets

 

534

609

827

873

921

CASH FLOW

Operating Cash Flow

 

93

165

124

128

134

Net Interest

(15)

(12)

(11)

4

5

Tax

(14)

(15)

(18)

(23)

(24)

Capex

(38)

(65)

(58)

(51)

(48)

Acquisitions/disposals

(93)

2

365

0

0

Financing

2

5

0

0

0

Dividends

(23)

(25)

(28)

(31)

(32)

Other

92

(6)

(5)

(5)

(5)

Net Cash Flow

3

49

368

23

30

Opening net debt/(cash)

 

256

246

223

(146)

(168)

HP finance leases initiated

0

0

0

0

0

Other

7

(26)

0

0

0

Closing net debt/(cash)

 

246

223

(146)

(168)

(198)

Source: Company accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by UDG Healthcare and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2016. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Mologen — Update 21 July 2016

Mologen

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.